Literature DB >> 16484653

Feasibility and cost efficiency of a diagnostic guideline for chronic polyneuropathy: a prospective implementation study.

A F J E Vrancken1, S Kalmijn, E Buskens, H Franssen, M Vermeulen, J H J Wokke, N C Notermans.   

Abstract

BACKGROUND: Extensive investigations are often performed to reveal the cause of chronic polyneuropathy. It is not known whether a restrictive diagnostic guideline improves cost efficiency without loss of diagnostic reliability.
METHODS: In a prospective multicentre study, a comparison was made between the workup in patients with chronic polyneuropathy before and after guideline implementation.
RESULTS: Three hundred and ten patients were included: 173 before and 137 after guideline implementation. In all patients, the diagnosis would remain the same if the workup was limited to the investigations in the guideline. After guideline implementation, the time to reach a diagnosis decreased by two weeks. There was a reduction of 33% in the number and costs of routine laboratory investigations/patient, and a reduction of 27% in the total number of laboratory tests/patient, despite low guideline adherence.
CONCLUSION: The implementation of a diagnostic guideline for chronic polyneuropathy can reduce diagnostic delay and the number and costs of investigations for each patient without loss of diagnostic reliability. Continuous evaluation strategies after guideline implementation may improve guideline adherence and cost efficiency.

Entities:  

Mesh:

Year:  2006        PMID: 16484653      PMCID: PMC2077697          DOI: 10.1136/jnnp.2005.073239

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  24 in total

Review 1.  Peripheral neuropathy.

Authors:  Richard A C Hughes
Journal:  BMJ       Date:  2002-02-23

Review 2.  Evaluating patients with suspected peripheral neuropathy: do the right thing, not everything.

Authors:  Rahman Pourmand
Journal:  Muscle Nerve       Date:  2002-08       Impact factor: 3.217

Review 3.  Peripheral neuropathy.

Authors:  John D England; Arthur K Asbury
Journal:  Lancet       Date:  2004-06-26       Impact factor: 79.321

4.  Clinical and laboratory assessment of distal peripheral nerves in Gulf War veterans and spouses.

Authors:  L E Davis; S A Eisen; F M Murphy; R Alpern; B J Parks; M Blanchard; D J Reda; M K King; F A Mithen; H K Kang
Journal:  Neurology       Date:  2004-09-28       Impact factor: 9.910

5.  Block design allowed for control of the Hawthorne effect in a randomized controlled trial of test ordering.

Authors:  Wim H J M Verstappen; Trudy van der Weijden; Gerben ter Riet; Jeremy Grimshaw; Ron Winkens; Richard P T M Grol
Journal:  J Clin Epidemiol       Date:  2004-11       Impact factor: 6.437

6.  [Management of polyneuropathy].

Authors:  P Bouche; T Maisonobe; N Le Forestier
Journal:  Rev Neurol (Paris)       Date:  1998-07       Impact factor: 2.607

7.  The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK.

Authors:  B K MacDonald; O C Cockerell; J W Sander; S D Shorvon
Journal:  Brain       Date:  2000-04       Impact factor: 13.501

8.  Chronic polyneuropathies in Vest-Agder, Norway.

Authors:  A Mygland ; P Monstad
Journal:  Eur J Neurol       Date:  2001-03       Impact factor: 6.089

9.  Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation in two Italian regions. I. Prevalence and general characteristics of the sample. Italian General Practitioner Study Group (IGPSG).

Authors: 
Journal:  Neurology       Date:  1995-10       Impact factor: 9.910

10.  A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy.

Authors:  R A C Hughes; T Umapathi; I A Gray; N A Gregson; M Noori; A S Pannala; A Proteggente; A V Swan
Journal:  Brain       Date:  2004-06-16       Impact factor: 13.501

View more
  1 in total

Review 1.  The epidemiology and risk factors of chronic polyneuropathy.

Authors:  Rens Hanewinckel; Marieke van Oijen; M Arfan Ikram; Pieter A van Doorn
Journal:  Eur J Epidemiol       Date:  2015-12-23       Impact factor: 8.082

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.